CP 94253 hydrochloride
Potent, selective 5-HT1B agonist (Ki values are 89, 2, 860, 49 and 1,600 nM for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively). Centrally active upon systemic administration in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 293.8. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.4 mL||17.02 mL||34.04 mL|
|5 mM||0.68 mL||3.4 mL||6.81 mL|
|10 mM||0.34 mL||1.7 mL||3.4 mL|
|50 mM||0.07 mL||0.34 mL||0.68 mL|
References are publications that support the products' biological activity.
Fish et al (1999) Aggression heightened by alcohol or social instigation in mice: reduction by the 5-HT(1B) receptor agonist CP-94,253. Psychopharmacology 146 391 PMID: 10550489
Knobelman et al (2000) Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J.Pharmacol.Exp.Ther. 292 1111 PMID: 10688630
If you know of a relevant reference for CP 94253 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: CP 94253 hydrochloride, supplier, Potent, selective, 5-HT1B, agonists, Serotonin, Receptors, CP94253, hydrochloride, 5-HT1B, Receptors, 5-HT1B, Receptors, Tocris Bioscience
6 Citations for CP 94253 hydrochloride
Citations are publications that use Tocris products. Selected citations for CP 94253 hydrochloride include:
Mansari et al (2015) Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Neuron 232 2343 PMID: 25665528
Hagan et al (2012) 5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse 66 1024 PMID: 22961814
Doslikova et al (2013) 5-HT2C receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated. J Neurosci 33 9800 PMID: 23739976
Eriksson et al (2013) Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11. Psychopharmacology (Berl) 18 1096 PMID: 23032875
McDevitt et al (2011) Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce expression of fear and depression-like behavior. Pain 69 780 PMID: 21353664
Heisler et al (2006) Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Biol Psychiatry 51 239 PMID: 16846858
Do you know of a great paper that uses CP 94253 hydrochloride from Tocris? If so please let us know.
Reviews for CP 94253 hydrochloride
There are currently no reviews for this product. Be the first to review CP 94253 hydrochloride and earn rewards!
Have you used CP 94253 hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.